Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

Will Merck (MRK) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Merck (MRK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.

Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up

by Zacks Equity Research

Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

by Kinjel Shah

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Company News for Oct 29, 2021

by Zacks Equity Research

Companies in The News Are: CAT,SIRI,OSTK,MRK

Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

by Zacks Equity Research

Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.

Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

by Zacks Equity Research

Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.

Mark Vickery headshot

Jobless Claims, Q3 GDP Lower than Expected

by Mark Vickery

Another big day for data ahead of the opening bell this morning, with some good news and a few disappointments.

Q3 GDP Grew Lower than Expected

by Zacks Equity Research

Q3 GDP Grew Lower than Expected

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 13.64% and 5.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

by Sweta Killa

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

by Zacks Equity Research

Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Should You Buy Merck & Co. (MRK) Ahead of Earnings?

by Zacks Equity Research

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Benjamin Rains headshot

Buy This Great High-Yield Dividend Stock?

by Benjamin Rains

Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29...

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

by Kinjel Shah

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Merck (MRK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)

by Zacks Equity Research

Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.